Experienced in Hemolytic Anemia

Peter G. Kerr

Clayton, VIC, AU 
Experienced in Hemolytic Anemia
Clayton, VIC, AU 
OverviewLocationsClinical Research

Overview

Peter Kerr practices in Clayton, Australia. Mr. Kerr is rated as an Experienced expert by MediFind in the treatment of Hemolytic Anemia. His top areas of expertise are Chronic Kidney Disease, End-Stage Renal Disease (ESRD), Reflux Nephropathy, Diabetic Nephropathy, and Kidney Transplant.

His clinical research consists of co-authoring 171 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles in the study of Hemolytic Anemia.

Gender
Male

Locations

Clayton, VIC, Australia
Other Locations
Melbourne, VIC, Australia
Clayton, QLD, Australia
VIC, Australia
Austin Health
Heidelberg, VIC, Australia
Brisbane, QLD, Australia
Canberra, ACT, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase 1b, Multicenter, Open-Label Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Mezagitamab (TAK-079) in Patients With Primary IgA Nephropathy in Combination With Stable Background Therapy
A Phase 1b, Multicenter, Open-Label Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Mezagitamab (TAK-079) in Patients With Primary IgA Nephropathy in Combination With Stable Background Therapy
Enrollment Status: Active_not_recruiting
Publish Date: May 28, 2025
Intervention Type: Drug
Study Drug: Mezagitamab
Study Phase: Phase 1

171 Total Publications

A randomized controlled trial of intravenous immunoglobulin vs standard of care for the treatment of chronic active antibody-mediated rejection in kidney transplant recipients.
A randomized controlled trial of intravenous immunoglobulin vs standard of care for the treatment of chronic active antibody-mediated rejection in kidney transplant recipients.
Journal: Kidney international
Published: March 16, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Kerr's expertise for a condition
ConditionClose
    View All 29 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile